|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006142,
umls-concept:C0069515,
umls-concept:C0205216,
umls-concept:C0205250,
umls-concept:C0229671,
umls-concept:C0279025,
umls-concept:C0430420,
umls-concept:C0871261,
umls-concept:C1704632,
umls-concept:C1704824,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
1995-6-5
|
|
pubmed:abstractText |
Decisions concerning the use of hormone therapy to treat metastatic breast cancer are made on the basis of the presence of estrogen receptor (ER). Despite the presence of ER, half of patients will not respond to hormone treatment. The purpose of this study was to determine the effect of overexpression of HER-2/neu on the response to hormone therapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Fadrozole,
http://linkedlifedata.com/resource/pubmed/chemical/Megestrol,
http://linkedlifedata.com/resource/pubmed/chemical/Megestrol Acetate,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Estrogen,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Progesterone,
http://linkedlifedata.com/resource/pubmed/chemical/Tamoxifen
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1129-35
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:7738618-Adult,
pubmed-meshheading:7738618-Aged,
pubmed-meshheading:7738618-Aged, 80 and over,
pubmed-meshheading:7738618-Antigens,
pubmed-meshheading:7738618-Breast Neoplasms,
pubmed-meshheading:7738618-Chi-Square Distribution,
pubmed-meshheading:7738618-Double-Blind Method,
pubmed-meshheading:7738618-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:7738618-Fadrozole,
pubmed-meshheading:7738618-Female,
pubmed-meshheading:7738618-Gene Amplification,
pubmed-meshheading:7738618-Humans,
pubmed-meshheading:7738618-Megestrol,
pubmed-meshheading:7738618-Megestrol Acetate,
pubmed-meshheading:7738618-Middle Aged,
pubmed-meshheading:7738618-Neoplasm Metastasis,
pubmed-meshheading:7738618-Receptor, erbB-2,
pubmed-meshheading:7738618-Receptors, Estrogen,
pubmed-meshheading:7738618-Receptors, Progesterone,
pubmed-meshheading:7738618-Regression Analysis,
pubmed-meshheading:7738618-Survival Analysis,
pubmed-meshheading:7738618-Tamoxifen,
pubmed-meshheading:7738618-Treatment Outcome
|
|
pubmed:year |
1995
|
|
pubmed:articleTitle |
Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.
|
|
pubmed:affiliation |
Department of Medicine, Pennsylvania State University College of Medicine, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Multicenter Study
|
